Emerging therapeutics in idiopathic inflammatory myopathy
Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of systemic autoimmune diseases characterized mainly by inflammation of muscle tissue. Although IIM traditionally encompasses polymyositis, dermatomyositis (DM), and inclusion body myositis, the disease concept has been changing in...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-01-01
|
| Series: | Indian Journal of Rheumatology |
| Subjects: | |
| Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=6;spage=153;epage=162;aulast=Sato |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832543008611893248 |
|---|---|
| author | Shinji Sato |
| author_facet | Shinji Sato |
| author_sort | Shinji Sato |
| collection | DOAJ |
| description | Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of systemic autoimmune diseases characterized mainly by inflammation of muscle tissue. Although IIM traditionally encompasses polymyositis, dermatomyositis (DM), and inclusion body myositis, the disease concept has been changing in association with progress in diagnostic techniques. Thus, the new disease entities of amyopathic DM (ADM) or clinically ADM and immune-mediated necrotizing myopathy have been recognized recently. Because of the variety of symptoms or low prevalence or difficulty in correct evaluation of muscle strength and function in IIM patients, no standard treatment strategies have been established yet. Currently, glucocorticoids remain the first line of treatment of IIMs, but in addition to these, several other immunosuppressive agents or intravenous immunoglobulin have been used in a variety of different combinations. However, due to clinical heterogeneity of these conditions as well as the number of therapeutic target organs, IIM therapy remains challenging, and refractory cases are especially difficult to treat. In recent years, new therapeutic approaches using biologics or Janus kinase inhibitors, plasma exchange therapy, and other agents have been evaluated for IIMs. However, validation of the efficacy of these new treatment options remains an issue to be resolved. In this article, the author reviews current treatment strategies and new emerging therapies for IIM patients. |
| format | Article |
| id | doaj-art-4b3e15ddc72e4c8280903292bb3c0fc0 |
| institution | Kabale University |
| issn | 0973-3698 0973-3701 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Indian Journal of Rheumatology |
| spelling | doaj-art-4b3e15ddc72e4c8280903292bb3c0fc02025-02-03T12:00:44ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012020-01-0115615316210.4103/injr.injr_124_20Emerging therapeutics in idiopathic inflammatory myopathyShinji SatoIdiopathic inflammatory myopathies (IIMs) are a heterogeneous group of systemic autoimmune diseases characterized mainly by inflammation of muscle tissue. Although IIM traditionally encompasses polymyositis, dermatomyositis (DM), and inclusion body myositis, the disease concept has been changing in association with progress in diagnostic techniques. Thus, the new disease entities of amyopathic DM (ADM) or clinically ADM and immune-mediated necrotizing myopathy have been recognized recently. Because of the variety of symptoms or low prevalence or difficulty in correct evaluation of muscle strength and function in IIM patients, no standard treatment strategies have been established yet. Currently, glucocorticoids remain the first line of treatment of IIMs, but in addition to these, several other immunosuppressive agents or intravenous immunoglobulin have been used in a variety of different combinations. However, due to clinical heterogeneity of these conditions as well as the number of therapeutic target organs, IIM therapy remains challenging, and refractory cases are especially difficult to treat. In recent years, new therapeutic approaches using biologics or Janus kinase inhibitors, plasma exchange therapy, and other agents have been evaluated for IIMs. However, validation of the efficacy of these new treatment options remains an issue to be resolved. In this article, the author reviews current treatment strategies and new emerging therapies for IIM patients.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=6;spage=153;epage=162;aulast=Satoclinically amyopathic dermatomyositisdermatomyositisinclusion body myositisinterstitial lung diseasemyositis-specific antibodypolymyositistreatment |
| spellingShingle | Shinji Sato Emerging therapeutics in idiopathic inflammatory myopathy Indian Journal of Rheumatology clinically amyopathic dermatomyositis dermatomyositis inclusion body myositis interstitial lung disease myositis-specific antibody polymyositis treatment |
| title | Emerging therapeutics in idiopathic inflammatory myopathy |
| title_full | Emerging therapeutics in idiopathic inflammatory myopathy |
| title_fullStr | Emerging therapeutics in idiopathic inflammatory myopathy |
| title_full_unstemmed | Emerging therapeutics in idiopathic inflammatory myopathy |
| title_short | Emerging therapeutics in idiopathic inflammatory myopathy |
| title_sort | emerging therapeutics in idiopathic inflammatory myopathy |
| topic | clinically amyopathic dermatomyositis dermatomyositis inclusion body myositis interstitial lung disease myositis-specific antibody polymyositis treatment |
| url | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=6;spage=153;epage=162;aulast=Sato |
| work_keys_str_mv | AT shinjisato emergingtherapeuticsinidiopathicinflammatorymyopathy |